UNSPSC 51142524: Doreptide

This classification denotes an antiparkinsonian agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 51K3U6Q5ZN. European Medicines Agency schedules Doreptide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06371MIG. Doreptide generally arises in the molecular formula C17H24N4O3.

UNSPSC 51142524 Doreptide is a Commodity code that in recent state and local solicitation activity encompasses procurement of pharmaceutical products, naloxone, drug deactivation systems, and generic multi-source medications with over-the-counter products for distribution through government health programs and community health initiatives. State and local governments buying under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple state and local jurisdictions. Issuing bodies range from individual counties (such as Seminole County, Florida) to statewide cooperative purchasing vehicles (such as the Minnesota Multistate Cooperative Purchasing Alliance) to state health commissions (such as the Texas Health and Human Services Commission). The work involves direct procurement of finished pharmaceutical products, management of supply chain relationships with authorized wholesalers, and compliance with FDA manufacturing standards, Drug Supply Chain Security Act requirements, and Good Manufacturing Practices certification. Vendors must navigate multi-tiered distribution models, maintain relationships with specific authorized wholesalers, provide detailed product coding and pricing information, and meet insurance and performance standards.

Recent activity spans Florida, Minnesota, Oregon (through MMCAP), and Texas. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building, fixed-fee pricing, and a two-year initial term plus one-year renewal option. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 (due March 26, 2026) through MMCAP to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026 and contract terms of two years for new vendors. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities outside traditional pharmacy benefit manager and group purchasing organization channels, framed as preliminary research informing future formal solicitation.